(NASDAQ: STRO) Sutro Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34%.
Sutro Biopharma's earnings in 2026 is -$191,086,000.On average, 14 Wall Street analysts forecast STRO's earnings for 2026 to be -$143,116,085, with the lowest STRO earnings forecast at -$255,552,960, and the highest STRO earnings forecast at -$18,265,380. On average, 13 Wall Street analysts forecast STRO's earnings for 2027 to be -$145,379,170, with the lowest STRO earnings forecast at -$226,328,352, and the highest STRO earnings forecast at -$79,323,936.
In 2028, STRO is forecast to generate -$219,754,472 in earnings, with the lowest earnings forecast at -$584,492,157 and the highest earnings forecast at -$87,325,911.